慢性自发性荨麻疹发病机制新见解
慢性自发性荨麻疹(CSU)是肥大细胞介导的炎症性疾病,表现为反复风团和/或血管性水肿且无明确外源诱因。已描述两种主要内型:自身过敏性(I型)由针对自身抗原的IgE自身抗体介导,自身免疫性(IIb型)由针对肥大细胞和嗜碱性粒细胞上IgE或FcεRI的IgG自身抗体介导。IIb型与更高疾病严重度、自身免疫共病、低总IgE水平及对抗组胺药和奥马珠单抗反应降低相关。除经典自身抗体机制外,非IgE依赖通路(MRGPRX2、神经免疫相互作用、凝血与补体级联激活、持续低度炎症、肠道微生物组改变和屏障功能受损)也参与CSU发病。靶向2型炎症的生物制剂和布鲁顿酪氨酸激酶小分子抑制剂等治疗进展凸显了这些机制见解的临床相关性,但相当比例患者仍控制不佳,需要改进生物标志物、细化内型分层和疾病修饰治疗策略。
要点
- CSU分自身过敏性(I型)和自身免疫性(IIb型)两种内型
- IIb型与更高疾病严重度、自身免疫共病及治疗反应降低相关
- 非IgE依赖通路(MRGPRX2、神经免疫、凝血补体等)参与发病
核心结论
- CSU是异质性免疫紊乱导致肥大细胞激活,涉及自身抗体和非IgE依赖通路。
研究设计与样本
- 综述,总结CSU多因素病理生理学、知识空白及新兴治疗概念。
主要发现
- 自身过敏性(I型)CSU由针对自身抗原的IgE自身抗体介导。
- 自身免疫性(IIb型)CSU由针对IgE或FcεRI的IgG自身抗体介导。
- IIb型CSU与更高疾病严重度、自身免疫共病、低总IgE水平相关。
- IIb型CSU对抗组胺药和奥马珠单抗反应降低。
- 非IgE依赖通路包括MRGPRX2、神经免疫、凝血补体、低度炎症、肠道微生物组和屏障功能。
临床怎么用
- 认识CSU内型有助于个体化治疗,IIb型可能对常规治疗反应不佳。
- 靶向2型炎症生物制剂和BTK抑制剂等新疗法具有临床相关性。
局限性
- 相当比例患者仍控制不佳,需改进生物标志物和内型分层。
- 需要疾病修饰治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic spontaneous urticaria (CSU) is a mast cell-mediated inflammatory disease marked by recurrent wheals and/or angioedema in the absence of identifiable external triggers. Once considered idiopathic, CSU is now recognized as a heterogeneous immunological disorder that results in mast cell activation. Two major endotypes have been described: autoallergic (type I) CSU, mediated by IgE autoantibodies directed against self-antigens, and autoimmune (type IIb) CSU, mediated by IgG autoantibodies targeting IgE or FcεRI on mast cells and basophils. Type IIb CSU is associated with higher disease severity, autoimmune comorbidities, low total IgE levels, and reduced responsiveness to antihistamines and omalizumab. Beyond classical autoantibody-mediated mechanisms, increasing evidence supports the contribution of non-IgE-dependent pathways in CSU pathogenesis. These include Mas-related G protein-coupled receptor X2 (MRGPRX2) - mediated mast cell activation, neuroimmune interactions, activation of coagulation and complement cascades, and persistent low-grade inflammation. Alterations of the gut microbiome and impaired barrier function have also been implicated in sustaining systemic immune activation and lowering mast cell activation thresholds in subsets of patients. Recent therapeutic advances, including biologics targeting type 2 inflammation and small-molecule inhibitors of intracellular signaling pathways such as Bruton's tyrosine kinase, highlight the clinical relevance of these mechanistic insights. However, a substantial proportion of patients remain inadequately controlled, underscoring the need for improved biomarkers, refined endotype stratification, and disease-modifying treatment strategies. This review summarizes current insights into the multifactorial pathophysiology of CSU, highlights remaining knowledge gaps, and discusses how emerging concepts may inform more precise, personalized, and potentially disease-modifying therapeutic approaches.
引用
- Zuberbier T, Bonnekoh H, Kocatürk E, et al. Insights into Pathogenesis of Chronic Spontaneous Urticaria. Br J Dermatol. 2026. PMID: 42455161. doi:10.1093/bjd/ljag277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。